Surface Plasmon Resonance: Cost-efficient, Label-free Bio-molecular Detection Processes Drive Adoption

A senior market analyst, at Future Market Insights discusses the changing dynamics of the surface Plasmon resonance market and how are biotechnology and pharmaceutical companies responding to the same.

Used for achieving detailed analysis of the interactions between biomolecules, surface Plasmon resonance (SPR) finds extensive applications in the fields of biotechnology and pharmaceuticals, for the production of bio-sensors, new drugs, and also for material sciences procedures testing. With the growth of healthcare infrastructure, the demand in the surface Plasmon resonance market is anticipated to witness higher rate of growth.

How will SPR procedures fare in assisting the development of innovative new drugs?

The prohibitive restrictions of time, cost, and reduced rate of success for drugs incorporating small molecules has generated a demand for faster and precise activity and characteristic measurements through the drug development life cycle.

For instance, the binding characteristics of small molecule towards a targeted protein compound with SPR allows accurate profiling of the molecules binding behavior. The process allows researchers to study the stability and speed of formation for new compounds, which can significantly affect the behavior of the medication.

Unlike other similar procedures, SPR has the added advantage of being able to provide results without any labels, that too in real time.

What are the major innovative products defining the future of SPR procedures?

A recent product by Bruker named the SierraTM SPR-32 makes use of an innovative frame-inject technology that provides new opportunities for mechanistic study on interactions of molecular interactions, with a faster rate of analysis. This is made possible through the pre-stabilization of the molecules surface through the application of a portion of molecular co-factors that comprise added buffers, prior to the injection process of the compound. This allows the kinetics of the compound to be monitored in a disassociated stage allowing major savings on time, and expenses on consumable items.

When being used in conjunction with spectrometry equipment, superlative results from high throughput screening activities can be achieved easily, making this technology a massive change for pharmaceutical development.

What is SPR’s role in disease control?

Researchers at the Monash University have developed an unique Surface Plasmon Resonance (SPR) sensor with the application of specialized antimonene materials, which can detect cancer-related bio markers such as MicroRNA-155 and Micro-RNA 21, with nearly 150,000 cases of early detection of cancer in the last year alone, through research conducted by The Australian Research Council Centre of Excellence in Future Low-Energy Electronics Technology.  The technology has increased the accuracy of 2D cancer detection by approximately 10,000 times.

Throw some light on the challenges facing the development of SPR-based point-of-care devices?

Key aspects such as the mass production of metallic nanostructures on the biomolecule substrates, lack of detection sensitivity capabilities, and prohibitive expenses for combining microfluidic chips with point of care equipment is significantly restricting the creation of such devices.

To know more? Download sample report.

About Sandali 225 Articles
A former journalist, Sandali is a content marketer with over 5 years of writing experience, across various industries including Food Innovation, Healthcare, and IoT and Technology. Sandali has been weaving corporate stories for organizations through different forms of impactful marketing content. Her key aim is to strategically align well-crafted narratives with business objectives, translating into a powerful communications platform for the company.